
CVSA Stock Forecast & Price Target
CVSA Analyst Ratings
Bulls say
Covista is poised for success in the healthcare education sector, with a strong focus on meeting the growing demand for healthcare professionals and a shareholder-friendly approach. The company's potential for margin expansion and strong vision for becoming a key player in the healthcare industry make it an attractive investment, receiving an OUTPERFORM rating.
Bears say
Covista is facing challenges with their Chamberlain segment, which has underperformed with weaker new starts, leading to a decline in the company's valuation. The company's partnership with Sallie Mae to finance additional loans for students beyond the new caps imposed by the Education Department could potentially limit future enrollment and pricing power. Additionally, the company's plan to expand through new Chamberlain campuses and potential M&A activity may be hindered by high valuation expectations for nursing schools and regulatory restrictions. Despite the company's growth in the Walden segment and opportunities in the medical and veterinary schools, Covista's stock valuation remains at a discount to its peers, indicating continued skepticism from investors.
This aggregate rating is based on analysts' research of Adtalem Global Education Inc and is not a guaranteed prediction by Public.com or investment advice.
CVSA Analyst Forecast & Price Prediction
Start investing in CVSA
Order type
Buy in
Order amount
Est. shares
0 shares